Gilead Sciences
在场
是其中之一......
- Forbes Global 2000 (#575);
- Fortune 500 (#154);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Gilead Sciences 是一家在股票代码 GILD (US) 下上市的公司。
Gilead Sciences 在 7 个国家有直接业务。Gilead Sciences 拥有 7家子公司，其中包括 Gilead Sciences Canada、Gilead Sciences EMEA 和 Gilead Sciences Germany。
他们在：
涉及Gilead Sciences的并购和融资。
- Gilead Sciences has announced the acquisition of CymaBay Therapeutics (公布2024二月15号).
高管
查看带有其 109 名主要高管的组织结构图
Gilead Sciences 搜索最多的简介
- Daniel O'Day, Chairman of the Board and Chief Executive Officer
- Kelly Kramer, Director
- Sandra Horning, Director
高管在Gilead Sciences变化
- Dietmar BergerDietmar Berger 将于20251月2作为 Chief Medical Officer 加入公司 (新闻发布的2024十二月18号).
- Merdad Parsey, Chief Medical Officer, 将于 20251月 退休 (新闻发布的2024七月18号).
创建提醒
跟踪 Gilead Sciences 的高管变动
药店
Gilead Sciences 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Gilead Sciences 的最新新闻稿
- Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease AASLD Meeting 2024
- Late Breaking Clinical Data and Real World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
- Gilead Sciences Announces Third Quarter 2024 Financial Results
- Kite to Highlight Industry Leading CAR T Cell Therapy Portfolio at ASH 2024 Including Positive Survival Outcomes in Both Clinical Trials and the Real World
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
- Gilead Presents Additional Efficacy Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
- Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday November 6 2024
- Gilead to Present Late Breaking Data Highlighting Antiviral Portfolio Innovative Research Pipeline and HIV Leadership at IDWeek 2024
- Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
- Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
- View more press releases Close
通过电子邮件
